Wall Street brokerages expect TherapeuticsMD Inc (NASDAQ:TXMD) to post ($0.09) earnings per share for the current quarter, according to Zacks. Five analysts have issued estimates for TherapeuticsMD’s earnings, with estimates ranging from ($0.11) to ($0.08). TherapeuticsMD reported earnings per share of ($0.13) in the same quarter last year, which suggests a positive year over year growth rate of 30.8%. The company is expected to announce its next earnings report on Thursday, November 2nd.

On average, analysts expect that TherapeuticsMD will report full year earnings of ($0.41) per share for the current financial year, with EPS estimates ranging from ($0.50) to ($0.35). For the next financial year, analysts expect that the company will post earnings of ($0.27) per share, with EPS estimates ranging from ($0.46) to ($0.05). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover TherapeuticsMD.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $4.25 million for the quarter, compared to the consensus estimate of $4.91 million. TherapeuticsMD had a negative net margin of 530.84% and a negative return on equity of 71.36%. The business’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.11) earnings per share.

A number of analysts have recently weighed in on TXMD shares. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $15.00 price objective on shares of TherapeuticsMD in a research note on Monday, April 17th. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Friday, May 12th. Stifel Nicolaus reissued a “buy” rating and set a $20.00 price objective on shares of TherapeuticsMD in a research note on Monday, April 24th. Cantor Fitzgerald reissued an “overweight” rating and set a $33.00 price objective on shares of TherapeuticsMD in a research note on Wednesday, May 10th. Finally, CIBC raised TherapeuticsMD from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 11th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. TherapeuticsMD currently has an average rating of “Buy” and a consensus price target of $16.14.

Shares of TherapeuticsMD (NASDAQ TXMD) traded down 0.18% during midday trading on Friday, reaching $5.66. 2,930,046 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $5.43 and a 200 day moving average price of $5.53. TherapeuticsMD has a 12 month low of $3.50 and a 12 month high of $8.30. The company’s market cap is $1.15 billion.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/12/brokerages-anticipate-therapeuticsmd-inc-txmd-to-announce-0-09-eps.html.

A number of hedge funds have recently made changes to their positions in the company. Principal Financial Group Inc. raised its stake in shares of TherapeuticsMD by 3.9% in the second quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after buying an additional 818 shares during the last quarter. Managed Account Services Inc. raised its stake in shares of TherapeuticsMD by 5.5% in the second quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock worth $101,000 after buying an additional 1,000 shares during the last quarter. Amalgamated Bank raised its stake in shares of TherapeuticsMD by 7.2% in the second quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after buying an additional 1,322 shares during the last quarter. Traynor Capital Management Inc. raised its stake in shares of TherapeuticsMD by 14.0% in the second quarter. Traynor Capital Management Inc. now owns 22,799 shares of the company’s stock worth $123,000 after buying an additional 2,799 shares during the last quarter. Finally, Greenwood Capital Associates LLC raised its stake in shares of TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock worth $146,000 after buying an additional 3,022 shares during the last quarter.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.